Selank Research: Anxiolytic Neuropeptide and GABAergic Signalling

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an anxiolytic research compound. It is structurally based on tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from IgG that has immunomodulatory and nootropic properties — extended with the Pro-Gly-Pro tripeptide to improve metabolic stability. Selank is registered as a pharmaceutical preparation in Russia and Ukraine.

Structural Design: Tuftsin Extended with Pro-Gly-Pro

The Selank sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro can be divided into two functional domains:

Tuftsin core (positions 1-4: Thr-Lys-Pro-Arg). Tuftsin is a naturally occurring immunomodulatory tetrapeptide generated from the Fc region of IgG by specific enzymatic cleavage. It binds to receptors on phagocytes, macrophages, and brain cells, and has been studied for immunostimulatory and neuromodulatory effects. The TKPR sequence represents the pharmacological core of Selank's receptor interactions.

Pro-Gly-Pro extension (positions 5-7). This C-terminal tripeptide is shared with Semax (which has the sequence Met-Glu-His-Phe-Pro-Gly-Pro). Pro-Gly-Pro serves as a carboxypeptidase-resistant stability element that prevents rapid C-terminal degradation. It is also independently bioactive — Pro-Gly-Pro has been studied as a leukocyte chemotactic factor. The shared Pro-Gly-Pro between Selank and Semax reflects a deliberate design strategy for stable neuropeptide research tools.

GABAergic and Anxiolytic Research

Published Selank research has most extensively examined effects on GABAergic signalling — the primary inhibitory neurotransmitter system. Research has examined:

GABA receptor interactions. Studies have examined Selank's influence on GABA-A receptor function in hippocampal and cortical preparations, with reported benzodiazepine-site modulation in some published models.

Anxiolytic behavioural pharmacology. Animal model studies have used elevated plus maze, open field, and other standard anxiety paradigms to characterise Selank's behavioural profile, reporting anxiolytic effects at lower doses than other standard reference compounds in published comparisons.

Stress marker modulation. HPA axis parameters including corticosterone levels and CRH expression have been examined in Selank-treated stressed animal models.

BDNF and Neuroprotective Research

Published research has examined Selank's effects on brain-derived neurotrophic factor (BDNF) expression in hippocampal and cortical tissue models. Kolomin et al. published research on Selank's influence on BDNF/TrkB signalling in the context of memory consolidation and synaptic plasticity. BDNF signalling connects Selank research to Semax research, as both peptides have been examined in BDNF expression studies despite their distinct structural origins and primary receptor targets.

Enkephalin System Research

One mechanistically interesting aspect of Selank research is its examined interaction with the enkephalin system. Published research has proposed that Selank inhibits enkephalin-degrading enzymes — particularly enkephalinase (neutral endopeptidase/NEP/CD10) — extending the half-life of endogenous met-enkephalin and leu-enkephalin. If confirmed, this mechanism would connect Selank's anxiolytic effects to enhanced endogenous opioid signalling rather than direct GABA receptor interaction.

Immunomodulatory Research

As a tuftsin derivative, Selank maintains tuftsin's immunomodulatory research interest. Published studies have examined effects on IL-6, interferon-gamma, and other cytokine production in immune cell models, as well as NK cell activity in stressed animal research. This immunomodulatory dimension distinguishes Selank from purely anxiolytic research tools.

Selank vs Semax: Research Tool Comparison

Published Research References

For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.

Related research peptides: NA Selank Amidate | Semax | Semax + Selank Blend
View Selank product and buy →

Enkephalin System: Degradation Inhibition Mechanism

The proposed enkephalin degradation inhibition mechanism is one of the more mechanistically distinctive aspects of Selank research. Enkephalins (Met-enkephalin: Tyr-Gly-Gly-Phe-Met and Leu-enkephalin: Tyr-Gly-Gly-Phe-Leu) are endogenous opioid pentapeptides that activate delta-opioid receptors (DOR) and mu-opioid receptors (MOR) with anxiolytic and analgesic effects.

Enkephalins have a plasma half-life of approximately 1 minute due to rapid cleavage by: neprilysin (NEP, neutral endopeptidase, CD10) at the Gly3-Phe4 bond, and aminopeptidase M (CD13) at the Tyr1-Gly2 bond. If Selank inhibits one or both of these degradation enzymes, the effective concentration and duration of endogenous enkephalin activity would be extended without directly activating opioid receptors.

Published research characterising this mechanism has used fluorometric enzyme assays with fluorescent substrate analogues, measuring neprilysin activity in brain membrane preparations in the presence and absence of Selank. Confirmation requires showing that Selank reduces enkephalin degradation in preparations containing neprilysin activity, and that this is accompanied by enhanced DOR-mediated signalling in cell models.

Tuftsin Receptor Biology

Tuftsin (Thr-Lys-Pro-Arg) — the parent tetrapeptide of Selank's N-terminal sequence — was discovered in 1970 by Najjar and Nishioka as a phagocytosis-stimulating factor derived from immunoglobulin G. Tuftsin's C-terminal Arg residue is essential for activity, and Selank retains this Arg at position 4.

The tuftsin receptor has not been definitively cloned or molecularly characterised, which complicates Selank receptor pharmacology research. Published research has used competitive binding assays with radiolabelled tuftsin to characterise binding sites on macrophages and neutrophils, and functional assays (phagocytosis stimulation, cytokine production) to assess downstream tuftsin/Selank pharmacology. The lack of a cloned, characterised tuftsin receptor means that reporter assays or receptor-overexpression systems are not currently available for Selank pharmacology research.

Frequently Asked Questions

Why is Selank registered as a pharmaceutical in Russia but classified as a research compound elsewhere?
Russia has a regulatory pathway for peptide bioregulators developed by the Saint Petersburg Institute of Bioregulation that follows different evidence standards than EMA or FDA approval processes. Selank received Russian registration based on safety data and clinical research conducted within the Russian regulatory framework. Outside Russia (EU, UK, USA), Selank has not completed the regulatory approval process required for pharmaceutical status and is therefore classified as a research compound. Signal Labs supplies Selank for laboratory and analytical research purposes only, consistent with its regulatory status in the UK.

What assay systems are most appropriate for Selank GABAergic research?
Whole-cell patch-clamp electrophysiology in hippocampal neurons is the gold standard for GABA-A receptor pharmacology. For higher-throughput approaches, FLIPR calcium assay using GABA-A-expressing cell lines (with co-expressed calcium indicator) or fluorescence-based chloride flux assays provide functional GABA-A readouts. NFATc-luciferase reporter systems (via calcium/calcineurin pathway) can indirectly report GABA-A Cl- channel activity. Competitive binding displacement assays using [3H]-flunitrazepam (benzodiazepine site) or [35S]-TBPS (chloride channel blocker site) characterise binding interactions at specific GABA-A receptor domains relevant to Selank's proposed GABAergic mechanism.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide